How close are pharma companies to develop a vaccine against Sars-CoV-2
Auszug aus dem Bericht :
Quelle: https://born2invest.com/articles/pharma-companies-vaccine-sars-cov-2/
Ongoing vaccine projects for the Covid-19 pandemic
There are currently at least 16 projects for vaccines against Sars-CoV-2 – nine by companies, seven by research institutes. However, not all Chinese projects are known. The active companies are Curevac (Germany), Janssen (owned by Johnson & Johnson, USA), Sanofi Pasteur (France), Moderna + NIAID (USA), Inovio + Wistar Institute (USA), Clover Biopharmaceuticals (China), Novavax (USA), Tonix Pharmaceuticals (USA), Altimmune (USA).
GSK and Dynavax also contribute with their adjuvants (potentiators for vaccines) to projects of other companies and research groups. Three of the companies – namely Curevac, Moderna and Inovio – are financially supported by CEPI, the Coalition for Epidemic Preparedness Innovations.
Stages of vaccine development
The development of each new vaccine is – in simple terms – a multi-stage process: analysis of the virus, the design of the active ingredient, testing on animals, which is followed by testing on volunteers, and finally the approval procedure in the EU (correspondingly in the U.S., China, Japan, etc.). |
